Trial · NCT01259089
Results by group58
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 58
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Elevated APL | 10 | participants | |
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Decreased leukocytes | 10 | participants | |
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Hypokalemia | 10 | participants | |
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Pruritis/dry skin | 5 | participants | |
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Hypocalcemia | 8 | participants | |
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Anemia | 4 | participants | |
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Mucositis | 6 | participants | |
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Decreased lymphocytes | 6 | participants | |
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Decreased platelets | 6 | participants | |
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Hypomagnesemia | 6 | participants | |
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Decreased neutrophils | 5 | participants | |
| Incidence of Reported Adverse Events in Phase I | Arm I | Diarrhea | 11 | participants | |
| Incidence of Reported Adverse Events in Phase I | Arm I | Skin rash | 9 | participants | |
| Incidence of Reported Adverse Events in Phase I | Arm I | Hyperglycemia | 0 | participants | |
| Incidence of Reported Adverse Events in Phase I | Arm I | Night blindness | 3 | participants | |
| Incidence of Reported Adverse Events in Phase I | Arm I | Hypoalbuminemia | 0 | participants | |
| Incidence of Reported Adverse Events in Phase I | Arm I | Fatigue | 8 | participants | |
| Incidence of Reported Adverse Events in Phase I | Arm I | Elevated AST | 1 | participants | |
| Incidence of Reported Adverse Events in Phase I | Arm I | Nausea | 8 | participants | |
| Incidence of Reported Adverse Events in Phase I | Arm I | Hyponatremia | 0 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01259089/results?page=2